067080 — Dae Hwa Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for Dae Hwa Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	117,159	131,912	141,359	149,409	143,060
Cost of Revenue
Gross Profit	43,673	46,099	45,406	53,244	47,826
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	115,965	129,099	139,696	143,188	135,523
Operating Profit	1,194	2,812	1,663	6,221	7,537
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,525	2,426	-456	1,513	4,779
Provision for Income Taxes
Net Income After Taxes	1,962	1,221	-514	830	2,330
Minority Interest
Net Income Before Extraordinary Items
Net Income	2,217	1,116	-1,147	531	1,654
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,217	1,116	-1,147	531	1,654
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	175	147	-59.1	40.8	-32.2
Dividends per Share